Acute Myelogenous Leukemia  >>  dexamethasone  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone / Generic mfg.
NCT00006240: Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Completed
2
US
sargramostim, dexamethasone, oral sodium phenylbutyrate
National Heart, Lung, and Blood Institute (NHLBI)
Leukemia
 
08/01
NCT01009931: Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies

Terminated
2
1
US
12-O-tetradecanoylphorbol-13-acetate, TPA, Dexamethasone, Dexamethasone sodium phosphate, Choline magnesium trisalicylate, Trilisate
Rutgers, The State University of New Jersey, Rutgers Cancer Institute of New Jersey, National Cancer Institute (NCI), Biosuccess Biotech Co., Ltd.
Leukemia
10/11
09/14
ISAKIDS, NCT03860844 / 2018-002697-45: Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Hourglass Jan 2022 - Dec 2022 : From trial in pediatrics with r/r AML/ALL
Terminated
2
67
Europe, US, RoW
Isatuximab, SAR650984, Sarclisa, Dexamethasone or equivalent, Fludarabine, Cytarabine, Liposomal daunorubicin, Daunorubicin (nonliposomal), Idarubicin, Filgrastim or equivalent, Mitoxantrone, Doxorubicin, Vincristine, Pegaspargase (PEG) Asparaginase, Cyclophosphamide, Etoposide, Methotrexate, L - Asparginase, Hydroxyurea, L - Asparaginase (Erwinase)
Sanofi
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
09/22
05/23
NCT01084252 / 2013-001418-13: Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Checkmark For multiple myeloma in Japanese patients
Jun 2019 - Jun 2019: For multiple myeloma in Japanese patients
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
1/2
351
Europe, US, RoW
Isatuximab SAR650984, Sarclisa, Dexamethasone
Sanofi
Hematological Malignancy
12/18
07/23
KCP-8602-801, NCT02649790: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
CCS1477-02, NCT04068597 / 2019-000104-15: Study to Evaluate CCS1477 in Haematological Malignancies

Recruiting
1/2
250
Europe, US
CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax
CellCentric Ltd.
Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
06/25
06/25

Download Options